ClinicalTrials.gg
CompletedNCT00749944Updated Aug 31, 2010Results posted

Assessing Neuropsychiatric Symptoms Including Depression, Anxiety, Irritability, and Suicidal Thoughts or Behavior in Subjects Quitting Smoking on Varenicline Tartrate or Placebo

A Phase 4 interventional study of varenicline and placebo in Smoking Cessation, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-08-31.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
68th of 110
110 · median 209
Started
2008
with 13 others
Phase 4
47 of 110
3 open now
Registered
29th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 68th largest by enrollment, is one of 14 that started in 2008, is one of 47 in phase 4, and was the 29th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

Study objective is to compare neuropsychiatric adverse events in subjects treated with varenicline or placebo in a controlled setting where both groups are experiencing nicotine withdrawal.

03

Conditions studied

  • Smoking Cessation

Browse trials for

Keywords

  • nicotine withdrawal, smoking cessation, varenicline
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • smokers who smoke >10 cigarettes/day and who have at least a moderate level of addiction as measured by the Fagerstrom Test for Nicotine Dependence (score >5)

Exclusion criteria

Exclusion Criteria:

  • Any neuropsychiatric disease including depression, history of suicidal thoughts or behavior, bipolar disorder.
  • Any unstable medical condition
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    varenicline

    Drug: varenicline

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • 1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)

    Also known as: Chantix, Champix

  • Drugplacebo

    1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Profile of Mood States (POMS): Total Mood Disturbance (TMD)

    POMS TMD were responses to 65 items in 6 subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor, Fatigue, and Confusion), on 'How you feel right now?' (scale:0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for Relaxed and Efficient in the Tension-Anxiety and Confusion subscales. TMD was the sum of the scores of all 6 subscales but weighting Vigor negatively. Summary results (TMD scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  2. Change From Baseline in the Profile of Mood States (POMS): Tension-Anxiety Subscale

    POMS Tension-Anxiety subscale data were responses to 9 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction except for Relaxed. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  3. Change From Baseline in the Profile of Mood States (POMS): Depression-Dejection Subscale

    POMS Depression-Dejection subscale data responses to 15 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  4. Change From Baseline in the Profile of Mood States (POMS): Anger-Hostility Subscale

    POMS Anger-Hostility subscale data were responses to 12 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  5. Change From Baseline in the Profile of Mood States (POMS): Vigor Subscale

    POMS Vigor subscale data were responses to 8 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  6. Change From Baseline in the Profile of Mood States (POMS): Fatigue Subscale

    POMS Fatigue subscale data were responses to 7 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  7. Change From Baseline in the Profile of Mood States (POMS): Confusion Subscale

    POMS Confusion subscale data were responses to 7 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction except for Efficient. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  8. Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score

    The MADRS measures the overall severity of depressive symptoms and is a 10-item checklist. Each item was rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  9. Change From Baseline in the Hamilton Anxiety Scale (HAM-A): Total Score

    HAM-A measures treatment-related changes in generalized anxiety symptoms and is a 14-item questionnaire. Each item was scored from 0 (not present) to 4 (very severe) and a lower score indicated less affected. Total scores ranged from 0 (not affected) to 56 (very severely affected).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  10. Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Aggression Total Score

    The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Aggression total score was calculated by summing the weighted scores in Q1 to 4. Scores for each question ranged from 0 (no events) to 5 (very severe events). Total scores ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of agressive behaviour in a week.

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  11. Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score

    The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Irritability total score was calculated by summing the items in Q5 to 6. Scores for each question ranged from 0 (not at all) to 5 (extreme). Total scores ranged from 0 (no irritability) to 10 (extreme irritability).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  12. Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score

    The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Suicidality total score was calculated by summing the items Q7 to 7b. Scores for Q7 ranged from 0 (none) to 6 (very extreme) and scores for Q7a to 7b ranged from 0 (none) to 5 (extreme). Total scores ranged from 0 (no suicidal tendency) to 16 (extreme/very extreme suicidal tendency).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  13. Change From Baseline in the Social Dysfunction and Aggression Scale (SDAS): Total Score

    The SDAS contains 11 items with 5 possible responses: 0=not present, 1=doubtful or very mild, 2=mild to moderate, 3=severe, and 4=extremely severe. The SDAS was collected 3 times a day during the inpatient abstinence period (BC). Total scores ranged from 0 (not present) to 44 (extremely severe).

    Time frame: Baseline B (Week 2) to Week 4 (Period BC)

  14. Change From Baseline in the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score

    The BIS-11 is a 30-item self-report questionnaire designed to assess general impulsiveness taking into account the multifactorial nature of the construct. Possible responses to each item were: 1=rarely/never, 2=occasionally, 3=often, and 4=almost always/always. Scores of Items 1, 7, 8, 9, 10, 12, 13, 15, 20, 29 and 30 were reversed when calculating the total score. Total score ranged from 30 (less impulsive) to 120 (more impulsive).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

Secondary outcomes

  1. Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Total Score

    The MNWS total score contains 9 items (urge to smoke; depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; difficulty staying asleep). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Total scores were the average score for all 9 items and ranged from 0 (no withdrawal symptoms) to 4 (extreme withdrawal symptoms).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  2. Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Negative Affect Domain Subscale

    The MNWS negative affect domain subscale contains 4 items (depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores were the average from all 4 items and ranged from 0 (no negative affect) to 4 (extreme negative affect).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  3. Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Insomnia Domain Subscale

    The MNWS insomnia domain subscale contains 2 items (difficulty going to sleep; difficulty staying asleep). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores were the average of the 2 items and ranged from 0 (no insomnia) to 4 (extreme insomnia).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  4. Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Urge to Smoke Subscale

    The MNWS urge to smoke subscale contains 1 item (urge to smoke) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no urge to smoke) to 4 (extreme urge to smoke).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  5. Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Restlessness Subscale

    The MNWS restlessness subscale contains 1 item (restlessness) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no restlessness) to 4 (extreme restlessness).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  6. Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Increased Appetite Subscale

    The MNWS increased appetite subscale contains 1 item (increased appetite) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no increased appetite) to 4 (extreme increased appetite).

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  7. Number of Participants Exceeding Thresholds for the Profile of Mood States (POMS): Total Score

    POMS total mood disturbance (TMD) summary results were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance). Participants exceeding the threshold had an increase from baseline of 1 standard deviation of the TMD baseline T-score plus 1 or more.

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  8. Number of Participants Exceeding Thresholds for the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score

    The MADRS measures the overall severity of depressive symptoms. Total score ranged from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Participants exceeding the threshold had a MADRS total score of more than 14 out of 60. MADRS total scores exceeding 14 may represent clinically notable effective symptomatology.

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  9. Number of Participants Exceeding Thresholds for the Hamilton Anxiety Scale (HAM-A): Total Score

    HAM-A measures treatment-related changes in generalized anxiety symptoms. Total scores ranged from 0 (not affected) to 56 (very severely affected). Participants exceeding the threshold had a HAM-A total score of more than or equal to 14 out of 56. HAM-A total scores of more than or equal to 14 may reflect clinically noteworthy levels of anxiety.

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  10. Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Agression Total Score

    The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Aggression total score ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of agressive behaviour in a week. Participants exceeding the threshold had an OAS-m Aggression total score of more than or equal to 3 out of any number with no upper limit depending on the frequency of agressive behaviour in a week. OAS-m Aggression total scores of more than or equal to 3 reflect clinically important aggression.

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  11. Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score

    The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Irritability total score ranged from 0 (no irritability) to 10 (extreme irritability). Participants exceeding the threshold had an OAS-m Irritability total score of more than or equal to 2 out of 10. OAS-m Irritability total scores of more than or equal to 2 reflect clinically important irritability.

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  12. Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score

    The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Suicidality total score ranged from 0 (no suicidal tendency) to 16 (extreme/very extreme suicidal tendency). No threshold criterion was determined for OAS-m Suicidality total score.

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  13. Number of Participants Exceeding Thresholds for the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score

    The BIS-11 is designed to assess general impulsiveness taking into account the multifactorial nature of the construct. Total score ranged from 30 (less impulsive) to 120 (more impulsive). Participants exceeding the threshold had a BIS-11 total score more than or equal to 70 out of 120. BIS-11 total scores of more than or equal to 70 could reflect clinically important and potentially pathological impulsivity.

    Time frame: Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).

  14. Number of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score

    SDAS total scores ranged from 0 (not present) to 44 (extremely severe). Participants exceeding the threshold had a SDAS total score of more than 6 out of 44.

    Time frame: Baseline B (Week 2) to Week 4 (Period BC)

  15. Number of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation

    Participants who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory, which was used to collect the information of cigarette or other nicotine use during the study) and who did not have carbon monoxide of more than 10 parts per million at any time from Week 9 to Week 12

    Time frame: Week 9 to Week 12

  16. Number of Participants With 7-day Point Prevalence of Abstinence (Smoking Cessation)

    Participants who reported no smoking and no use of other nicotine-containing products since the last study visit (during treatment) in the previous 7 days and who did not have carbon monoxide of more than 10 parts per million for that observation (if measured).

    Time frame: Week 5 to Week 13

  17. Change From Baseline in the Number of Cigarettes Smoked Per Day

    Time frame: Baseline (Week 0) to Week 2

07

Results

Posted Aug 9, 2010

Participant flow

Participant flow — Overall Study
MilestoneVareniclinePlacebo
Started5555
Completed5054
Not completed51
Withdrew: Lost to follow-up21
Withdrew: Other10
Withdrew: Withdrawal by subject20

Outcome measures

PrimaryChange From Baseline in the Profile of Mood States (POMS): Total Mood Disturbance (TMD)

POMS TMD were responses to 65 items in 6 subscales (Tension-Anxiety, Depression-Dejection, Anger-Hostility, Vigor, Fatigue, and Confusion), on 'How you feel right now?' (scale:0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for Relaxed and Efficient in the Tension-Anxiety and Confusion subscales. TMD was the sum of the scores of all 6 subscales but weighting Vigor negatively. Summary results (TMD scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Profile of Mood States (POMS): Total Mood Disturbance (TMD)
scores on a scaleVareniclinePlacebo
Period AB (n=55, 55)0.06 ± 0.39-0.66 ± 0.36
Period AC (n=55, 55)0.30 ± 0.35-0.17 ± 0.36
Period AD (n=55, 55)0.95 ± 0.430.03 ± 0.41
Period AE (n=55, 55)0.72 ± 0.360.22 ± 0.37
Period BC (n=53, 54)0.48 ± 0.350.91 ± 0.31
Period BD (n=53, 54)1.07 ± 0.471.04 ± 0.39
Period BE (n=54, 54)0.59 ± 0.370.96 ± 0.36
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.72 · 95% CI -0.33 to 1.77
  • Varenicline vs Placebo · Difference (change from baseline): 0.46 · 95% CI -0.50 to 1.43
  • Varenicline vs Placebo · Difference (change from baseline): 0.92 · 95% CI -0.27 to 2.11
  • Varenicline vs Placebo · Difference (change from baseline): 0.50 · 95% CI -0.52 to 1.53
  • Varenicline vs Placebo · Difference (change from baseline): -0.43 · 95% CI -1.35 to 0.50Mixed Models Analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.03 · 95% CI -1.18 to 1.24
  • Varenicline vs Placebo · Difference (change from baseline): -0.37 · 95% CI -1.37 to 0.63Mixed Models Analysis
PrimaryChange From Baseline in the Profile of Mood States (POMS): Tension-Anxiety Subscale

POMS Tension-Anxiety subscale data were responses to 9 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction except for Relaxed. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Profile of Mood States (POMS): Tension-Anxiety Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=55, 55)0.30 ± 0.30-0.31 ± 0.25
Period AC (n=55, 55)0.15 ± 0.25-0.26 ± 0.21
Period AD (n=55, 55)0.31 ± 0.24-0.18 ± 0.27
Period AE (n=55, 55)0.01 ± 0.24-0.43 ± 0.20
Period BC (n=53, 54)-0.01 ± 0.24-0.10 ± 0.25
Period BD (n=53, 54)0.06 ± 0.23-0.16 ± 0.29
Period BE (n=54, 54)-0.35 ± 0.19-0.58 ± 0.21
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.62 · 95% CI -0.15 to 1.39
  • Varenicline vs Placebo · Difference (change from baseline): 0.41 · 95% CI -0.24 to 1.07
  • Varenicline vs Placebo · Difference (change from baseline): 0.48 · 95% CI -0.26 to 1.22
  • Varenicline vs Placebo · Difference (change from baseline): 0.44 · 95% CI -0.18 to 1.06
  • Varenicline vs Placebo · Difference (change from baseline): 0.10 · 95% CI -0.58 to 0.78
  • Varenicline vs Placebo · Difference (change from baseline): 0.22 · 95% CI -0.48 to 0.92
  • Varenicline vs Placebo · Difference (change from baseline): 0.23 · 95% CI -0.26 to 0.72
PrimaryChange From Baseline in the Profile of Mood States (POMS): Depression-Dejection Subscale

POMS Depression-Dejection subscale data responses to 15 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Profile of Mood States (POMS): Depression-Dejection Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=55, 55)0.38 ± 0.25-0.24 ± 0.18
Period AC (n=55, 55)0.50 ± 0.24-0.24 ± 0.13
Period AD (n=55, 55)0.56 ± 0.27-0.10 ± 0.16
Period AE (n=55, 55)0.44 ± 0.240.00 ± 0.19
Period BC (n=53, 54)0.51 ± 0.270.03 ± 0.13
Period BD (n=53, 54)0.49 ± 0.320.10 ± 0.14
Period BE (n=54, 54)0.32 ± 0.230.23 ± 0.20
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.62 · 95% CI -0.00 to 1.24
  • Varenicline vs Placebo · Difference (change from baseline): 0.73 · 95% CI 0.18 to 1.29
  • Varenicline vs Placebo · Difference (change from baseline): 0.66 · 95% CI 0.02 to 1.30
  • Varenicline vs Placebo · Difference (change from baseline): 0.43 · 95% CI -0.19 to 1.05
  • Varenicline vs Placebo · Difference (change from baseline): 0.48 · 95% CI -0.09 to 1.05
  • Varenicline vs Placebo · Difference (change from baseline): 0.39 · 95% CI -0.28 to 1.06
  • Varenicline vs Placebo · Difference (change from baseline): 0.09 · 95% CI -0.47 to 0.65
PrimaryChange From Baseline in the Profile of Mood States (POMS): Anger-Hostility Subscale

POMS Anger-Hostility subscale data were responses to 12 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Profile of Mood States (POMS): Anger-Hostility Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=55, 55)0.16 ± 0.36-0.69 ± 0.25
Period AC (n=55, 55)-0.04 ± 0.31-0.89 ± 0.16
Period AD (n=55, 55)0.24 ± 0.36-1.00 ± 0.22
Period AE (n=55, 55)0.15 ± 0.30-0.68 ± 0.15
Period BC (n=53, 54)-0.00 ± 0.29-0.52 ± 0.15
Period BD (n=53, 54)0.22 ± 0.41-0.65 ± 0.19
Period BE (n=54, 54)-0.05 ± 0.25-0.43 ± 0.18
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.85 · 95% CI -0.02 to 1.72Mixed Models Analysis included baseline, treatment (t; fixed), subject (random), day (d; fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.85 · 95% CI 0.16 to 1.54Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 1.24 · 95% CI 0.39 to 2.08Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.83 · 95% CI 0.14 to 1.52Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.52 · 95% CI -0.06 to 1.09Mixed Models Analysis included baseline, t (fixed), subject (random), time (fixed), d (fixed), and interactions for t-by-time, t-by-d, time-by-d and t-by-time-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.88 · 95% CI 0.05 to 1.70Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.38 · 95% CI -0.12 to 0.88Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
PrimaryChange From Baseline in the Profile of Mood States (POMS): Vigor Subscale

POMS Vigor subscale data were responses to 8 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Profile of Mood States (POMS): Vigor Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=55, 55)0.16 ± 0.860.98 ± 0.75
Period AC (n=55, 55)-1.34 ± 0.87-1.15 ± 0.75
Period AD (n=55, 55)-3.30 ± 1.18-1.14 ± 0.97
Period AE (n=55, 55)-2.80 ± 1.00-1.82 ± 0.91
Period BC (n=53, 54)-1.49 ± 0.81-3.44 ± 0.83
Period BD (n=53, 54)-3.22 ± 1.25-3.22 ± 1.11
Period BE (n=54, 54)-2.28 ± 1.02-3.37 ± 1.04
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): -0.82 · 95% CI -3.07 to 1.43Mixed Models Analysis included baseline, treatment (t; fixed), subject (random), day (d; fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): -0.19 · 95% CI -2.47 to 2.08Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): -2.15 · 95% CI -5.19 to 0.89Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): -0.98 · 95% CI -3.67 to 1.70Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 1.95 · 95% CI -0.36 to 4.26Mixed Models Analysis included baseline, t (fixed), subject (random), time (fixed), d (fixed), and interactions for t-by-time, t-by-d, time-by-d and t-by-time-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): -0.01 · 95% CI -3.32 to 3.30Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 1.09 · 95% CI -1.80 to 3.97Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
PrimaryChange From Baseline in the Profile of Mood States (POMS): Fatigue Subscale

POMS Fatigue subscale data were responses to 7 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Profile of Mood States (POMS): Fatigue Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=55, 55)-0.14 ± 0.29-0.65 ± 0.29
Period AC (n=55, 55)-0.29 ± 0.28-0.83 ± 0.24
Period AD (n=55, 55)-0.58 ± 0.26-0.76 ± 0.27
Period AE (n=55, 55)-0.32 ± 0.27-0.59 ± 0.24
Period BC (n=53, 54)0.37 ± 0.32-0.22 ± 0.23
Period BD (n=53, 54)-0.20 ± 0.29-0.13 ± 0.30
Period BE (n=54, 54)-0.16 ± 0.29-0.26 ± 0.25
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.52 · 95% CI -0.29 to 1.32Mixed Models Analysis included baseline, treatment (t; fixed), subject (random), day (d; fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.54 · 95% CI -0.17 to 1.25Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.18 · 95% CI -0.55 to 0.92Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.26 · 95% CI -0.46 to 0.99Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.59 · 95% CI -0.19 to 1.37Mixed Models Analysis included baseline, t (fixed), subject (random), time (fixed), d (fixed), and interactions for t-by-time, t-by-d, time-by-d and t-by-time-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): -0.08 · 95% CI -0.91 to 0.76Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.10 · 95% CI -0.65 to 0.85Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
PrimaryChange From Baseline in the Profile of Mood States (POMS): Confusion Subscale

POMS Confusion subscale data were responses to 7 items regarding 'How you feel right now?' on a scale of 0=not at all, 1=a little, 2=moderately, 3=quite a bit, and 4=extremely. All items were rated in the same direction except for Efficient. Summary results (subscale scores) were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Profile of Mood States (POMS): Confusion Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=55, 55)0.14 ± 0.19-0.09 ± 0.12
Period AC (n=55, 55)0.03 ± 0.17-0.18 ± 0.10
Period AD (n=55, 55)0.10 ± 0.18-0.11 ± 0.13
Period AE (n=55, 55)-0.01 ± 0.15-0.03 ± 0.13
Period BC (n=53, 54)0.02 ± 0.22-0.07 ± 0.11
Period BD (n=53, 54)0.07 ± 0.22-0.02 ± 0.15
Period BE (n=54, 54)-0.14 ± 0.18-0.02 ± 0.16
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.23 · 95% CI -0.20 to 0.65Mixed Models Analysis included baseline, treatment (t; fixed), subject (random), day (d; fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.21 · 95% CI -0.17 to 0.58Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.21 · 95% CI -0.23 to 0.65Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.02 · 95% CI -0.37 to 0.41Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.09 · 95% CI -0.41 to 0.59Mixed Models Analysis included baseline, t (fixed), subject (random), time (fixed), d (fixed), and interactions for t-by-time, t-by-d, time-by-d and t-by-time-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): 0.10 · 95% CI -0.44 to 0.63Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
  • Varenicline vs Placebo · Difference (change from baseline): -0.12 · 95% CI -0.58 to 0.34Mixed Models Analysis included baseline, t (fixed), subject (random), d (fixed), and interaction for t-by-d.
PrimaryChange From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score

The MADRS measures the overall severity of depressive symptoms and is a 10-item checklist. Each item was rated on a scale of 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)1.05 ± 0.370.83 ± 0.25
Period AC (n=54, 54)2.28 ± 0.351.84 ± 0.30
Period AD (n=54, 54)1.19 ± 0.291.41 ± 0.37
Period AE (n=55, 54)1.52 ± 0.211.50 ± 0.28
Period BC (n=53, 54)2.27 ± 0.501.69 ± 0.48
Period BD (n=53, 54)-0.10 ± 0.350.33 ± 0.53
Period BE (n=53, 54)0.40 ± 0.240.49 ± 0.30
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.22 · 95% CI -0.66 to 1.10Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.44 · 95% CI -0.46 to 1.35Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.22 · 95% CI -1.16 to 0.71Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.03 · 95% CI -0.68 to 0.73Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.58 · 95% CI -0.79 to 1.96Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.43 · 95% CI -1.69 to 0.82Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.09 · 95% CI -0.86 to 0.68Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
PrimaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A): Total Score

HAM-A measures treatment-related changes in generalized anxiety symptoms and is a 14-item questionnaire. Each item was scored from 0 (not present) to 4 (very severe) and a lower score indicated less affected. Total scores ranged from 0 (not affected) to 56 (very severely affected).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A): Total Score
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)1.01 ± 0.320.75 ± 0.27
Period AC (n=54, 54)2.69 ± 0.372.16 ± 0.28
Period AD (n=54, 54)1.95 ± 0.411.86 ± 0.42
Period AE (n=55, 54)1.75 ± 0.281.61 ± 0.26
Period BC (n=53, 54)3.15 ± 0.562.65 ± 0.47
Period BD (n=53, 54)0.74 ± 0.470.77 ± 0.62
Period BE (n=53, 54)0.73 ± 0.300.81 ± 0.29
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.27 · 95% CI -0.55 to 1.08Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.53 · 95% CI -0.39 to 1.46Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.09 · 95% CI -1.08 to 1.25Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.14 · 95% CI -0.62 to 0.90Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.50 · 95% CI -0.94 to 1.95Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.03 · 95% CI -1.57 to 1.51Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.08 · 95% CI -0.91 to 0.75Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
PrimaryChange From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Aggression Total Score

The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Aggression total score was calculated by summing the weighted scores in Q1 to 4. Scores for each question ranged from 0 (no events) to 5 (very severe events). Total scores ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of agressive behaviour in a week.

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Aggression Total Score
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)0.13 ± 0.270.48 ± 0.66
Period AC (n=54, 54)0.82 ± 0.370.72 ± 0.39
Period AD (n=54, 54)2.24 ± 1.750.75 ± 0.34
Period AE (n=55, 54)1.27 ± 0.700.77 ± 0.48
Period BC (n=53, 54)0.83 ± 0.630.22 ± 0.38
Period BD (n=53, 54)1.94 ± 2.27-0.15 ± 0.44
Period BE (n=53, 54)1.00 ± 0.88-0.13 ± 0.23
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): -0.35 · 95% CI -1.76 to 1.06Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.11 · 95% CI -0.96 to 1.17Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 1.49 · 95% CI -1.94 to 4.91Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.50 · 95% CI -1.18 to 2.18Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.61 · 95% CI -0.85 to 2.07Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 2.10 · 95% CI -2.60 to 6.79Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 1.13 · 95% CI -0.70 to 2.96Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
PrimaryChange From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score

The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Irritability total score was calculated by summing the items in Q5 to 6. Scores for each question ranged from 0 (not at all) to 5 (extreme). Total scores ranged from 0 (no irritability) to 10 (extreme irritability).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)0.01 ± 0.100.01 ± 0.09
Period AC (n=54, 54)0.43 ± 0.100.41 ± 0.09
Period AD (n=54, 54)0.46 ± 0.170.35 ± 0.17
Period AE (n=55, 54)0.32 ± 0.100.24 ± 0.08
Period BC (n=53, 54)0.82 ± 0.160.78 ± 0.16
Period BD (n=53, 54)0.53 ± 0.190.35 ± 0.24
Period BE (n=53, 54)0.38 ± 0.110.25 ± 0.08
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.00 · 95% CI -0.26 to 0.27Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.02 · 95% CI -0.25 to 0.29Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.10 · 95% CI -0.37 to 0.58Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.08 · 95% CI -0.17 to 0.34Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.04 · 95% CI -0.40 to 0.48Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.17 · 95% CI -0.44 to 0.78Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.13 · 95% CI -0.14 to 0.40Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
PrimaryChange From Baseline in the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score

The OAS-m contains 3 scales: Aggression (Questions \[Q\]1 to 4), Irritability (Q5 to 6), and Suicidality (Q7 to 7b). Suicidality total score was calculated by summing the items Q7 to 7b. Scores for Q7 ranged from 0 (none) to 6 (very extreme) and scores for Q7a to 7b ranged from 0 (none) to 5 (extreme). Total scores ranged from 0 (no suicidal tendency) to 16 (extreme/very extreme suicidal tendency).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale

No measurements were reported for this outcome.

PrimaryChange From Baseline in the Social Dysfunction and Aggression Scale (SDAS): Total Score

The SDAS contains 11 items with 5 possible responses: 0=not present, 1=doubtful or very mild, 2=mild to moderate, 3=severe, and 4=extremely severe. The SDAS was collected 3 times a day during the inpatient abstinence period (BC). Total scores ranged from 0 (not present) to 44 (extremely severe).

Time frame:
Baseline B (Week 2) to Week 4 (Period BC)
Reported as:
Least squares mean · scores on a scale

No measurements were reported for this outcome.

PrimaryChange From Baseline in the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score

The BIS-11 is a 30-item self-report questionnaire designed to assess general impulsiveness taking into account the multifactorial nature of the construct. Possible responses to each item were: 1=rarely/never, 2=occasionally, 3=often, and 4=almost always/always. Scores of Items 1, 7, 8, 9, 10, 12, 13, 15, 20, 29 and 30 were reversed when calculating the total score. Total score ranged from 30 (less impulsive) to 120 (more impulsive).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)0.34 ± 0.56-0.07 ± 0.50
Period AC (n=54, 54)0.45 ± 0.620.37 ± 0.53
Period AD (n=54, 54)1.34 ± 0.741.28 ± 1.03
Period AE (n=55, 54)1.19 ± 0.690.90 ± 0.64
Period BC (n=53, 54)0.04 ± 0.490.97 ± 0.43
Period BD (n=53, 54)1.07 ± 0.491.81 ± 0.92
Period BE (n=53, 54)0.85 ± 0.521.28 ± 0.44
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.41 · 95% CI -1.09 to 1.90Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.08 · 95% CI -1.54 to 1.71Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.06 · 95% CI -2.47 to 2.60Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.29 · 95% CI -1.57 to 2.15Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.94 · 95% CI -2.23 to 0.36Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.74 · 95% CI -2.81 to 1.33Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.43 · 95% CI -1.78 to 0.92Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
SecondaryChange From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Total Score

The MNWS total score contains 9 items (urge to smoke; depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating; restlessness; increased appetite; difficulty going to sleep; difficulty staying asleep). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Total scores were the average score for all 9 items and ranged from 0 (no withdrawal symptoms) to 4 (extreme withdrawal symptoms).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Total Score
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)0.13 ± 0.040.05 ± 0.04
Period AC (n=54, 54)0.10 ± 0.030.11 ± 0.03
Period AD (n=54, 54)0.07 ± 0.030.05 ± 0.03
Period AE (n=55, 54)-0.01 ± 0.020.04 ± 0.03
Period BC (n=53, 54)-0.04 ± 0.040.10 ± 0.06
Period BD (n=53, 54)-0.08 ± 0.030.02 ± 0.04
Period BE (n=53, 54)-0.15 ± 0.01-0.05 ± 0.03
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.08 · 95% CI -0.04 to 0.19Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.01 · 95% CI -0.11 to 0.08Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.02 · 95% CI -0.06 to 0.09Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.05 · 95% CI -0.11 to 0.02Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.14 · 95% CI -0.27 to -0.01Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.10 · 95% CI -0.21 to 0.01Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.10 · 95% CI -0.17 to -0.03Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
SecondaryChange From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Negative Affect Domain Subscale

The MNWS negative affect domain subscale contains 4 items (depressed mood; irritability, frustration, or anger; anxiety; difficulty concentrating). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores were the average from all 4 items and ranged from 0 (no negative affect) to 4 (extreme negative affect).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Negative Affect Domain Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)0.06 ± 0.030.01 ± 0.02
Period AC (n=54, 54)0.10 ± 0.030.09 ± 0.03
Period AD (n=54, 54)0.07 ± 0.030.03 ± 0.03
Period AE (n=55, 54)0.05 ± 0.020.07 ± 0.03
Period BC (n=53, 54)0.07 ± 0.050.15 ± 0.05
Period BD (n=53, 54)-0.01 ± 0.030.02 ± 0.05
Period BE (n=53, 54)-0.02 ± 0.020.03 ± 0.03
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.05 · 95% CI -0.03 to 0.12Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.00 · 95% CI -0.08 to 0.09Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.03 · 95% CI -0.04 to 0.11Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.01 · 95% CI -0.08 to 0.05Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.08 · 95% CI -0.22 to 0.06Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.03 · 95% CI -0.14 to 0.09Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.05 · 95% CI -0.11 to 0.02Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
SecondaryChange From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Insomnia Domain Subscale

The MNWS insomnia domain subscale contains 2 items (difficulty going to sleep; difficulty staying asleep). Each item was rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores were the average of the 2 items and ranged from 0 (no insomnia) to 4 (extreme insomnia).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Insomnia Domain Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)0.07 ± 0.040.12 ± 0.06
Period AC (n=54, 54)0.15 ± 0.040.17 ± 0.05
Period AD (n=54, 54)0.04 ± 0.030.10 ± 0.04
Period AE (n=55, 54)0.06 ± 0.020.13 ± 0.06
Period BC (n=53, 54)0.14 ± 0.070.09 ± 0.08
Period BD (n=53, 54)-0.04 ± 0.050.01 ± 0.06
Period BE (n=53, 54)-0.06 ± 0.02-0.01 ± 0.06
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): -0.06 · 95% CI -0.20 to 0.09Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.02 · 95% CI -0.15 to 0.12Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.05 · 95% CI -0.15 to 0.04Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.08 · 95% CI -0.20 to 0.04Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.05 · 95% CI -0.17 to 0.27Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.05 · 95% CI -0.21 to 0.10Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.05 · 95% CI -0.17 to 0.07Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
SecondaryChange From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Urge to Smoke Subscale

The MNWS urge to smoke subscale contains 1 item (urge to smoke) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no urge to smoke) to 4 (extreme urge to smoke).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Urge to Smoke Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)-0.60 ± 0.10-0.29 ± 0.09
Period AC (n=54, 54)-1.40 ± 0.09-0.97 ± 0.09
Period AD (n=54, 54)-2.17 ± 0.12-2.03 ± 0.12
Period AE (n=55, 54)-1.90 ± 0.09-1.55 ± 0.09
Period BC (n=53, 54)-1.59 ± 0.12-1.14 ± 0.14
Period BD (n=53, 54)-1.66 ± 0.14-1.58 ± 0.15
Period BE (n=53, 54)-1.56 ± 0.10-1.29 ± 0.11
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline: -0.30 · 95% CI -0.58 to -0.02Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline: -0.44 · 95% CI -0.69 to -0.19Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline: -0.14 · 95% CI -0.47 to 0.20Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline: -0.35 · 95% CI -0.61 to -0.09Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline: -0.45 · 95% CI -0.83 to -0.07Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline: -0.08 · 95% CI -0.50 to 0.34Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline: -0.27 · 95% CI -0.57 to 0.02Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
SecondaryChange From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Restlessness Subscale

The MNWS restlessness subscale contains 1 item (restlessness) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no restlessness) to 4 (extreme restlessness).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Restlessness Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)0.06 ± 0.040.08 ± 0.04
Period AC (n=54, 54)0.10 ± 0.040.11 ± 0.04
Period AD (n=54, 54)0.09 ± 0.040.04 ± 0.03
Period AE (n=55, 54)0.03 ± 0.020.05 ± 0.03
Period BC (n=53, 54)0.07 ± 0.050.08 ± 0.05
Period BD (n=53, 54)0.03 ± 0.02-0.03 ± 0.01
Period BE (n=53, 54)-0.04 ± 0.02-0.03 ± 0.03
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): -0.02 · 95% CI -0.12 to 0.08Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.02 · 95% CI -0.12 to 0.08Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.05 · 95% CI -0.04 to 0.14Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.01 · 95% CI -0.07 to 0.04Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.01 · 95% CI -0.15 to 0.13Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): 0.06 · 95% CI 0.01 to 0.10Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.02 · 95% CI -0.08 to 0.04Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
SecondaryChange From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Increased Appetite Subscale

The MNWS increased appetite subscale contains 1 item (increased appetite) rated from 0 to 4 where 0=not at all, 1=slight, 2=moderate, 3=quite a bit, and 4=extreme. Scores ranged from 0 (no increased appetite) to 4 (extreme increased appetite).

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Minnesota Nicotine Withdrawal Scale (MNWS): Increased Appetite Subscale
scores on a scaleVareniclinePlacebo
Period AB (n=54, 54)0.14 ± 0.070.02 ± 0.05
Period AC (n=54, 54)0.10 ± 0.050.12 ± 0.06
Period AD (n=54, 54)0.11 ± 0.090.15 ± 0.09
Period AE (n=55, 54)-0.00 ± 0.050.04 ± 0.06
Period BC (n=53, 54)-0.03 ± 0.070.16 ± 0.08
Period BD (n=53, 54)-0.01 ± 0.090.15 ± 0.10
Period BE (n=53, 54)-0.10 ± 0.04-0.03 ± 0.06
Statistical analysis
  • Varenicline vs Placebo · Difference (change from baseline): 0.12 · 95% CI -0.05 to 0.28Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.02 · 95% CI -0.19 to 0.14Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.04 · 95% CI -0.29 to 0.22Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.04 · 95% CI -0.20 to 0.13Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.19 · 95% CI -0.40 to 0.01Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.16 · 95% CI -0.42 to 0.10Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
  • Varenicline vs Placebo · Difference (change from baseline): -0.07 · 95% CI -0.22 to 008Mixed Models Analysis included baseline, treatment (fixed effect), subject (random effect), week (fixed effect), and interaction of treatment-by-week.
SecondaryNumber of Participants Exceeding Thresholds for the Profile of Mood States (POMS): Total Score

POMS total mood disturbance (TMD) summary results were presented as transformed T-scores ranging from 30 (less disturbance) to 80 (more disturbance). Participants exceeding the threshold had an increase from baseline of 1 standard deviation of the TMD baseline T-score plus 1 or more.

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Number · participants
Number of Participants Exceeding Thresholds for the Profile of Mood States (POMS): Total Score
participantsVareniclinePlacebo
Period AB (n=55, 55)1411
Period AC (n=55, 55)3235
Period AD (n=55, 55)3738
Period AE (n=55, 55)3838
Period BC (n=53, 54)2733
Period BD (n=53, 54)3036
Period BE (n=54, 54)3238
Statistical analysis
  • Varenicline vs Placebo · Odds ratio (or): 1.4 · 95% CI 0.6 to 3.3Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.8 · 95% CI 0.4 to 1.7Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.9 · 95% CI 0.4 to 2.1Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.0 · 95% CI 0.4 to 2.2Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.7 · 95% CI 0.3 to 1.4Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.7 · 95% CI 0.3 to 1.4Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.6 · 95% CI 0.3 to 1.4Cochran-Mantel-Haenszel
SecondaryNumber of Participants Exceeding Thresholds for the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score

The MADRS measures the overall severity of depressive symptoms. Total score ranged from 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Participants exceeding the threshold had a MADRS total score of more than 14 out of 60. MADRS total scores exceeding 14 may represent clinically notable effective symptomatology.

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Number · participants
Number of Participants Exceeding Thresholds for the Montgomery-Asberg Depression Rating Scale (MADRS): Total Score
participantsVareniclinePlacebo
Period AB (n=54, 54)20
Period AC (n=54, 54)73
Period AD (n=54, 54)83
Period AE (n=55, 54)118
Period BC (n=53, 54)53
Period BD (n=53, 54)63
Period BE (n=54, 54)98
Statistical analysis
  • Varenicline vs Placebo · Odds ratio (or): 2.5 · 95% CI 0.6 to 10.4Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 3.0 · 95% CI 0.7 to 11.8Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.4 · 95% CI 0.5 to 3.9Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.8 · 95% CI 0.4 to 7.8Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 2.2 · 95% CI 0.5 to 9.2Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.2 · 95% CI 0.4 to 3.2Cochran-Mantel-Haenszel
SecondaryNumber of Participants Exceeding Thresholds for the Hamilton Anxiety Scale (HAM-A): Total Score

HAM-A measures treatment-related changes in generalized anxiety symptoms. Total scores ranged from 0 (not affected) to 56 (very severely affected). Participants exceeding the threshold had a HAM-A total score of more than or equal to 14 out of 56. HAM-A total scores of more than or equal to 14 may reflect clinically noteworthy levels of anxiety.

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Number · participants
Number of Participants Exceeding Thresholds for the Hamilton Anxiety Scale (HAM-A): Total Score
participantsVareniclinePlacebo
Period AB (n=54, 54)02
Period AC (n=54, 54)97
Period AD (n=54, 54)127
Period AE (n=55, 54)1610
Period BC (n=53, 54)96
Period BD (n=53, 54)126
Period BE (n=54, 54)169
Statistical analysis
  • Varenicline vs Placebo · Odds ratio (or): 1.3 · 95% CI 0.5 to 3.9Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.9 · 95% CI 0.7 to 5.3Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.8 · 95% CI 0.7 to 4.4Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.6 · 95% CI 0.5 to 5.0Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 2.3 · 95% CI 0.8 to 6.8Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 2.1 · 95% CI 0.8 to 5.3Cochran-Mantel-Haenszel
SecondaryNumber of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Agression Total Score

The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Aggression total score ranged from 0 (no aggression) to any number with no upper limit depending on the frequency of agressive behaviour in a week. Participants exceeding the threshold had an OAS-m Aggression total score of more than or equal to 3 out of any number with no upper limit depending on the frequency of agressive behaviour in a week. OAS-m Aggression total scores of more than or equal to 3 reflect clinically important aggression.

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Number · participants
Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Agression Total Score
participantsVareniclinePlacebo
Period AB (n=54, 54)96
Period AC (n=54, 54)2021
Period AD (n=54, 54)2123
Period AE (n=55, 54)2831
Period BC (n=53, 54)1519
Period BD (n=53, 54)1821
Period BE (n=54, 54)2730
Statistical analysis
  • Varenicline vs Placebo · Odds ratio (or): 1.6 · 95% CI 0.5 to 4.9Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.9 · 95% CI 0.4 to 2.0Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.9 · 95% CI 0.4 to 1.8Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.8 · 95% CI 0.4 to 1.6Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.7 · 95% CI 0.3 to 1.6Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.8 · 95% CI 0.4 to 1.8Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.8 · 95% CI 0.4 to 1.7Cochran-Mantel-Haenszel
SecondaryNumber of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score

The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Irritability total score ranged from 0 (no irritability) to 10 (extreme irritability). Participants exceeding the threshold had an OAS-m Irritability total score of more than or equal to 2 out of 10. OAS-m Irritability total scores of more than or equal to 2 reflect clinically important irritability.

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Number · participants
Number of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Irritability Total Score
participantsVareniclinePlacebo
Period AB (n=54, 54)1011
Period AC (n=54, 54)3234
Period AD (n=54, 54)3636
Period AE (n=55, 54)4139
Period BC (n=53, 54)3131
Period BD (n=53, 54)3533
Period BE (n=54, 54)4038
Statistical analysis
  • Varenicline vs Placebo · Odds ratio (or): 0.9 · 95% CI 0.3 to 2.3Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.9 · 95% CI 0.4 to 1.9Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.0 · 95% CI 0.4 to 2.2Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.1 · 95% CI 0.5 to 2.6Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.0 · 95% CI 0.5 to 2.3Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.2 · 95% CI 0.6 to 2.7Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.2 · 95% CI 0.5 to 2.8Cochran-Mantel-Haenszel
SecondaryNumber of Participants Exceeding Thresholds for the Overt Aggression Scale (Modified) (OAS-m): Suicidality Total Score

The OAS-m contains 3 scales: Aggression, Irritability, and Suicidality. Suicidality total score ranged from 0 (no suicidal tendency) to 16 (extreme/very extreme suicidal tendency). No threshold criterion was determined for OAS-m Suicidality total score.

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryNumber of Participants Exceeding Thresholds for the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score

The BIS-11 is designed to assess general impulsiveness taking into account the multifactorial nature of the construct. Total score ranged from 30 (less impulsive) to 120 (more impulsive). Participants exceeding the threshold had a BIS-11 total score more than or equal to 70 out of 120. BIS-11 total scores of more than or equal to 70 could reflect clinically important and potentially pathological impulsivity.

Time frame:
Baseline A (Week 0) to Week 2 (Period AB), Week 4 (Period AC), Week 12 or relapse (Period AD), and Week 12 (Period AE). Baseline B (Week 2) to Week 4 (Period BC), Week 12 or relapse (Period BD), and Week 12 (Period BE).
Reported as:
Number · participants
Number of Participants Exceeding Thresholds for the Barratt Impulsiveness Scale - Version 11 (BIS-11): Total Score
participantsVareniclinePlacebo
Period AB (n=54, 54)10
Period AC (n=54, 54)12
Period AD (n=54, 54)12
Period AE (n=55, 54)55
Period BC (n=53, 54)12
Period BD (n=53, 54)12
Period BE (n=54, 54)55
Statistical analysis
  • Varenicline vs Placebo · Odds ratio (or): 0.5 · 95% CI 0.0 to 5.6Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.5 · 95% CI 0.0 to 5.6Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.0 · 95% CI 0.3 to 3.6Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.5 · 95% CI 0.0 to 5.7Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 0.5 · 95% CI 0.0 to 5.7Cochran-Mantel-Haenszel
  • Varenicline vs Placebo · Odds ratio (or): 1.0 · 95% CI 0.3 to 3.7Cochran-Mantel-Haenszel
SecondaryNumber of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score

SDAS total scores ranged from 0 (not present) to 44 (extremely severe). Participants exceeding the threshold had a SDAS total score of more than 6 out of 44.

Time frame:
Baseline B (Week 2) to Week 4 (Period BC)
Reported as:
Number · participants
Number of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score
participantsVareniclinePlacebo
Number of Participants Exceeding Thresholds for the Social Dysfunction and Aggression Scale (SDAS): Total Score21
Statistical analysis
  • Varenicline vs Placebo · Odds ratio (or): 2.1 · 95% CI 0.2 to 23.6Cochran-Mantel-Haenszel
SecondaryNumber of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation

Participants who reported no smoking and no use of other nicotine-containing products since the last study visit (on the Nicotine Use Inventory, which was used to collect the information of cigarette or other nicotine use during the study) and who did not have carbon monoxide of more than 10 parts per million at any time from Week 9 to Week 12

Time frame:
Week 9 to Week 12
Reported as:
Number · participants
Number of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation
participantsVareniclinePlacebo
Number of Participants With Carbon Monoxide Confirmed Daily Smoking Cessation1610
SecondaryNumber of Participants With 7-day Point Prevalence of Abstinence (Smoking Cessation)

Participants who reported no smoking and no use of other nicotine-containing products since the last study visit (during treatment) in the previous 7 days and who did not have carbon monoxide of more than 10 parts per million for that observation (if measured).

Time frame:
Week 5 to Week 13
Reported as:
Number · participants
Number of Participants With 7-day Point Prevalence of Abstinence (Smoking Cessation)
participantsVareniclinePlacebo
Week 5 (n=55, 55)1916
Week 6 (n=55, 55)2312
Week 7 (n=55, 55)2017
Week 8 (n=55, 55)2115
Week 9 (n=55, 55)2514
Week 10 (n=55, 55)1717
Week 11 (n=55, 55)2018
Week 12 (n=55, 55)1915
Week 13 (n=55, 55)2315
SecondaryChange From Baseline in the Number of Cigarettes Smoked Per Day
Time frame:
Baseline (Week 0) to Week 2
Reported as:
Mean · cigarettes smoked per day
Change From Baseline in the Number of Cigarettes Smoked Per Day
cigarettes smoked per dayVareniclinePlacebo
Day 2 (n=55, 54)-0.1 ± 3.6-0.2 ± 3.7
Day 3 (n=55, 54)-0.6 ± 4.10.0 ± 3.9
Day 4 (n=55, 54)-1.8 ± 5.0-0.3 ± 3.7
Day 5 (n=55, 54)-1.0 ± 5.2-0.4 ± 4.0
Day 6 (n=54, 54)-1.3 ± 5.90.1 ± 4.5
Day 7 (n=54, 54)-1.8 ± 4.9-0.3 ± 5.0
Day 8 (n=54, 54)-1.7 ± 5.00.4 ± 4.3
Day 9 (n=52, 54)-1.0 ± 5.10.1 ± 4.2
Day 10 (n=52, 54)-1.7 ± 5.7-0.4 ± 6.1
Day 11 (n=53, 54)-1.8 ± 5.3-0.4 ± 6.3
Day 12 (n=53, 54)-0.7 ± 6.6-0.2 ± 6.3
Day 13 (n=53, 54)-1.4 ± 5.6-0.1 ± 6.1
Day 14 (n=36, 38)-17.2 ± 8.6-15.7 ± 6.6

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Varenicline—0/55 (0%)54/55 (98.2%)
Placebo—0/55 (0%)52/55 (94.5%)
Most frequent other events
Showing 10 of 78
Most frequent other events
EventVareniclinePlacebo
NauseaGastrointestinal disorders18/5516/55
HeadacheNervous system disorders18/5515/55
IrritabilityGeneral disorders17/5517/55
Upper respiratory tract infectionInfections and infestations12/5517/55
InsomniaPsychiatric disorders17/5510/55
SomnolenceNervous system disorders11/558/55
Abdominal painGastrointestinal disorders10/555/55
Chapped lipsGastrointestinal disorders10/557/55
Increased appetiteMetabolism and nutrition disorders4/559/55
ConstipationGastrointestinal disorders8/553/55

Baseline characteristics

Age, Customized
Age, Customized(Participants)VareniclinePlaceboTotal
Between 18 and 44 years474794
Between 45 and 64 years7815
>= 65 years101
Sex: Female, Male
Sex: Female, Male(Participants)VareniclinePlaceboTotal
Female221537
Male334073
08

Study locations

2 sites
  • Pfizer Investigational Site
    Austin, Texas 78759, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78217, United States
09

References and documents

Publications

  • Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry. 2011 Jun 1;69(11):1075-82. doi: 10.1016/j.biopsych.2010.12.005. Epub 2011 Feb 3. PubMed 21295286 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Jul 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2008
First posted
Sep 10, 2008
Start
Sep 2008
Primary completionActual
Jul 2009
CompletionActual
Aug 2009
Results first posted
Aug 9, 2010
Last update
Aug 31, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00749944
Lead sponsor
Pfizer
First posted
Sep 10, 2008
Start date
Sep 2008
Primary completion
Jul 2009
Completion
Aug 2009
Results posted
Aug 9, 2010
Last update
Aug 31, 2010

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion